Millennium Capital Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Millennium Capital Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$774K	Buy	4,892 +156	+3%	+$21.1K	0.42%	56
2026 Q1	$605K	Buy	4,736 +12	+0.3%	+$1.5K	0.37%	58
2025 Q4	$576K	Buy	4,724 +1,503	+47%	+$172K	0.34%	64
2025 Q3	$323K	Sell	3,221 -215	-6%	-$19.4K	0.19%	93
2025 Q2	$285K	Sell	3,436 -1,500	-30%	-$120K	0.19%	94
2025 Q1	$400K	Sell	4,936 -10	-0.2%	-$894	0.3%	63
2024 Q4	$445K	Hold	4,946	–	–	0.3%	60
2024 Q3	$489K	Buy	4,946 +44	+0.9%	+$4.32K	0.32%	57
2024 Q2	$454K	Sell	4,902 -24	-0.5%	-$2.15K	0.3%	63
2024 Q1	$467K	Buy	4,926 +1,100	+29%	+$102K	0.33%	59
2023 Q4	$342K	Buy	3,826 +15	+0.4%	+$1.11K	0.26%	68
2023 Q3	$278K	Sell	3,811 -45	-1%	-$3.6K	0.24%	78
2023 Q2	$321K	Buy	3,856 +506	+15%	+$42.3K	0.26%	69
2023 Q1	$255K	Buy	3,350 +120	+4%	+$9.96K	0.23%	82
2022 Q4	$268K	Buy	3,230 +60	+2%	+$4.86K	0.27%	76
2022 Q3	$251K	Sell	3,170 -648	-17%	-$54.6K	0.27%	78
2022 Q2	$284K	Sell	3,818 -7	-0.2%	-$525	0.28%	71
2022 Q1	$344K	Hold	3,825	–	–	0.28%	65
2021 Q4	$428K	Buy	+3,825	New	+$461K	0.33%	58

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Millennium Capital Advisors's XBI Position: Q2 2026 in Review

Millennium Capital Advisors increased its State Street SPDR S&P Biotech ETF (XBI) stake by 3.3% in Q2 2026, buying an estimated $21.1K and bringing the position to 4,892 shares worth $774K. The position accounts for 0.42% of the portfolio, ranked #56.

Millennium Capital Advisors first reported a position in XBI in Q4 2021 and has held it in 19 quarters since. 932 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Millennium Capital Advisors held 4,892 shares of State Street SPDR S&P Biotech ETF worth $774K as of Q2 2026.
Millennium Capital Advisors bought 156 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $21.1K.
State Street SPDR S&P Biotech ETF made up 0.42% of Millennium Capital Advisors's portfolio in Q2 2026, its #56 holding.
Millennium Capital Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2021 and has held it in 19 quarters since.
932 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Millennium Capital Advisors's 13F filing for Q2 2026, filed 28 Jul 2026.